- Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally, with artificial intelligence, automation, and new robotic platforms, remaining central to the company’s long-term product roadmap.
- Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely.
- The SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery.
- The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries.
- SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, who discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities.
Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating expenses. “Our goal was really to reduce the cost without compromising performance,” Dr. Srivastava said during the interview, describing affordability as the first step toward what he calls the democratization of robotic surgery (https://ibn.fm/9uyO4).
That philosophy has shaped development of the company’s flagship SSi Mantra surgical robotic platform, which supports multiple specialties including cardiac surgery, often considered the most challenging of surgeries. According to the company, the system incorporates three to five modular robotic arms, an open-console surgeon workstation, 3D 4K visualization, more than 40 robotic surgical instruments and integrated telesurgery capabilities.
Dr. Srivastava’s perspective is informed by decades as a robotic cardiac surgeon. Before founding SS Innovations, he performed more than 1,400 robotic procedures, including more than 750 totally endoscopic coronary artery bypass surgeries. After returning to India in 2011 to establish robotic surgery programs, he concluded that many hospitals simply could not justify the cost of existing robotic systems.
To address that challenge, he invested approximately $4.5 million of his own savings to launch SS Innovations, initially assembling a team of ten engineers working from his home before securing outside financing. Manufacturing and engineering operations in India also helped lower development costs while allowing the company to move rapidly through successive generations of its robotic platform.
According to Dr. Srivastava, the latest SSi Mantra generation was redesigned from the ground up in approximately five months, benefiting from close collaboration between surgeons and engineers throughout development. That interaction between clinicians and developers remains central to the company’s product strategy. Rather than separating engineering from end users, Dr. Srivastava said his teams continually refine features based on practical surgical experience, shortening development cycles while focusing on usability for physicians.
Beyond the robotic platform itself, SS Innovations has invested heavily in infrastructure intended to support broader adoption.
Among the company’s most visible initiatives is telesurgery. While remote robotic surgery remains an emerging field, SS Innovations has completed more than 170 telesurgeries, including more than 20 cardiac telesurgery procedures. According to the company, it is currently the only surgical robotic platform that has been used for cardiac telesurgery. The fact that the system has repeatedly demonstrated its effectiveness in the challenging field of cardiac surgery points to its world class capability for all the other types of soft tissue surgeries.
The technology is designed to allow experienced surgeons to remotely guide or perform procedures using high-speed communications, potentially reducing the need for patients to travel long distances to specialized medical centers. Dr. Srivastava described telesurgery not as a standalone commercial opportunity today, but as part of a broader strategy to extend expert surgical care into smaller communities.
The company has also developed teleproctoring capabilities, allowing experienced surgeons to mentor physicians remotely during procedures. Mobile training facilities, including a dedicated robotic surgery training bus, have been deployed to increase physician education and public awareness.
Commercial expansion has continued alongside technology development. According to the company, SS Innovations has now installed more than 200 robotic systems and completed more than 11,700 robotic procedures worldwide. The platform has also received regulatory approvals across numerous international markets, while the company continues pursuing both U.S. FDA clearance and European CE certification.
During a November 2025 interview at Nasdaq MarketSite, Dr. Srivastava said the company expects the United States to become an important future market because many hospitals continue to face economic barriers when evaluating robotic surgery platforms (https://ibn.fm/OEiZz). He also highlighted the system’s ability to support robotic cardiac surgery, an area where relatively few robotic platforms currently compete.
Artificial intelligence also forms part of SS Innovations’ long-term roadmap. In the Nasdaq interview, Dr. Srivastava explained that AI already contributes to safety functions within the SSi Mantra platform while future development efforts are focused on advanced imaging, semi-automated procedures and eventually greater levels of surgical automation.
Looking further ahead, the company is also exploring specialty-specific robotic systems, pediatric applications, mobile operating units and robotics designed for disaster response and military medicine, although many of these initiatives remain in development.
For more information, visit the company’s website at www.SSInnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
